Action of melatonin on bone marrow depression induced by cyclophosphamide in acute toxicity phase

Neuroendocrinology Letters

Volumn 30, Issue 5, 2009, Pages 582-591

  Pacini, Nicola ^a   Borziani, Fabio ^a  

^a Private Laboratory of Physiology Prof Luigi Di Bella   (Italy)

Author keywords

Bone marrow; Cyclophosphamide; Erythrocyte; Hematopoiesis; L ascorbic acid; Leukocyte; Leukopenia; Melatonin; Platelet; tocopheryl acetate

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CYCLOPHOSPHAMIDE; MELATONIN;

ANIMAL EXPERIMENT; ARTICLE; BONE MARROW DEPRESSION; CONTROLLED STUDY; DRUG ACTIVITY; NONHUMAN; RAT;

EID: 77649268511     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (127)

1. Acun̄a-Castroviejo D, Martín M, Macías M et al. (2001). Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res. 30(2):65-74.
2. Akbulut H, Icli F, Büyükcelik A et al. (1999). The role of granulocyte-macrophage-colony stimulating factor, cortisol, and melatonin in the regulation of the circadian rhythms of peripheral blood cells in healthy volunteers and patients with breast cancer. J Pineal Res. 26(1):1-8.
3. Aleandri V, Spina V, Morini A (1996). The pineal gland and reproduction. Hum Reprod Update. 2(3):225-35.
4. Allegra M, Furtmüller PG, Regelsberger G et al. (2001). Mechanism of reaction of melatonin with human myeloperoxidase. Biochem Biophys Res Commun. 282(2):380-6.
5. Arushanian EB, Beǐer EV, Mastiagina OA et al. (2006). Melatonin effect on the hematological indices of healthy humans. Eksp Klin Farmakol. 69(5):36-8.
6. Baltaci AK, Mogulkoc R, Kul A et al. (2004). Opposite effects of zinc and melatonin on thyroid hormones in rats. Toxicology. 195(1):69-75.
7. Baydas G, Kutlu S, Naziroglu M et al. (2003). Inhibitory effects of melatonin on neural lipid peroxidation induced by intra-cerebroventricularly administered homocysteine. J Pineal Res. 34(1):36-9.
8. Bejarano I, Redondo PC, Espino J et al. (2009). Melatonin induces mitochondrial-mediated apoptosis in human myeloid HL-60 cells. J Pineal Res. 46(4):392-400.
9. Beydemir S, Gülçin I (2004). Effects of melatonin on carbonic anhydrase from human erythrocytes in vitro and from rat erythrocytes in vivo. J Enzyme lnhib Med Chem. 19(2):193-7.
10. Brömme HJ, Mörke W, Peschke D et al. (2000). Scavenging effect of melatonin on hydroxyl radicals generated by alloxan. J Pineal Res. 29(4):201-8.
11. Cacciapaglia F, Spadaccio C, Chello M et al. (2009). Apoptotic molecular mechanisms implicated in autoimmune diseases. Eur Rev Med Pharmacol Sci. 13(1):23-40.
12. Cardell M, Jung FJ, Zhai W et al. (2008). Acute allograft rejection and immunosuppression: influence on endogenous melatonin secretion. J Pineal Res. 44(3):261-6.
13. Cardinali DP, Del Zar MM, Vacas Ml (1993). The effects of melatonin in human platelets. Acta Physiol Pharmacol Ther Latinoam. 43(1-2):1-13.
14. Caroleo MC, Doria G, Nisticò G (1994). Melatonin restores immunodepression in aged and cyclophosphamide-treated Mice. Ann N Y Acad Sci. 719:343-52.
15. Carrillo-Vico A, García-Pergañeda A, Naji L et al. (2003). Expression of membrane and nuclear melatonin receptor mRNA and protein in the mouse immune system. Cell Mol Life Sci. 60(10):2272-8.
16. Carrillo-Vico A, Calvo JR, Abreu P et al. (2004). Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. Faseb J. 18(3):537-9.
17. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ (2005). A review of the multiple actions of melatonin on the immune system. Endocrine. 27(2):189-200.
18. Champier J, Claustrat B, Besançon R, et al. (1997). Evidence for tryptophan hydroxylase and hydroxy-indol-O-methyl-transferase mRNAs in human blood platelets. Life Sci. 60(24):2191-7.
19. Cheng Y, Feng Z, Zhang QZ, Zhang JT (2006). Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol Sin. 27(2):129-39.
20. Ciftçi M, Bilici D, Küfrevioǧlu Ol (2001). Effects of melatonin on enzyme activities of glucose-6-phosphate dehydrogenase from human erythrocytes in vitro and from rat erythrocytes in vivo. Pharmacol Res. 44(1):7-11.
21. Conti A, Conconi S, Hertens E et al. (2000). Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res. 28(4):193-202.
22. Currier NL, Sun LZ, Miller SC (2000). Exogenous melatonin: quantitative enhancement in vivo of cells mediating non-specific immunity. J Neuroimmunol. 104(2):101-8.
23. Di Bella L, Rossi MT, Pellegrino N et al. ( 1969). Ruolo del sistema abenulo-epifisario nella regolazione del tasso piastrinemico. Boll Soc Ital Biol Sper. Vol. XLV, N. 20 bis.
24. Di Bella L, Rossi MT, Scalera G (1979, a). Perspectives in pineal functions. Prog Brain Res. 52:475-8.
25. Di Bella L, Rossi MT, Gualano L, Scalera G (1979, b). Effect of the simultaneous action of melatonin and ADP in megakaryocytes in vitro. Boll Soc Ital Biol Sper. 55(5):389-93.
26. Di Bella L, Gualano L, Rossi MT, Scalera G (1979, c). The action of melatonin (MLT) on platelet metabolism in vitro. Boll Soc Ital Biol Sper. 55(4):323-6.
27. Di Bella L, Scalera G, Rossi MT, Gualano L (1979, d). L'Aggregazione Piastrinica in presenza di melatonina. Bollettino societá italiana di fisiologia. Riunione primaverile dell'anno sociale 1978/79.
28. Di Bella L, Rossi MT (1980). Red Blood cells generation and melatonin. International Symposium on melatonin. Bremen, 28-30 September 1980.
29. Di Bella L, Bruschi C, Gualano L (2002). Melatonin effects on megakaryocyte membrane patch-clamp outward K+ current. Med Sci Monit. 8(12):BR527-31.
30. Di Bella L, Gualano L (2006). Key aspects of melatonin physiology: thirty years of research. Neuro Endocrinol Lett. 27(4):425-32.
31. Drazen DL, Bilu D, Bilbo SD, Nelson RJ (2001). Melatonin enhancement of splenocyte proliferation is attenuated by luzindole, a melatonin receptor antagonist. Am J Physiol Regul lntegr Comp Physiol. 280(5):R1476-82.
32. Droin N, Jacquel A, Guery L et al. (2009). Various functions of caspases in hematopoiesis. Front Biosci. 14:2358-71.
33. Falcón J, Besseau L, Fuentès M et al. (2009). Structural and functional evolution of the pineal melatonin system in vertebrates. Ann N Y Acad Sci. 1163:101-11.
34. Feng Z, Qin C, Chang Y, Zhang JT (2006). Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic Biol Med. 40(1):101-9.
35. Finocchiaro LM, Arzt ES, Fernández-Castelo S, Criscuolo M et al. (1988). Serotonin and melatonin synthesis in peripheral blood mononuclear cells: stimulation by interferon-gamma as part of an immunomodulatory pathway. J Interferon Res. 8(6):705-16.
36. Formigli L, Ibba Manneschi L,Tani A et al. (1997). Vitamin E prevents neutrophil accumulation and attenuates tissue damage in ischemic-reperfused human skeletal muscle. Histol Histopathol. 12(3):663-9.
37. Ghielmini M, Pagani O, Pampallona, de Jong J et al. (1999). Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin end etoposide in advanced lung cancer. Br J Cancer. 80(7):1058-61.
38. Goda K, Hamane Y, Kishimoto R, Ogishi Y (1999). Radical scavenging properties of tryptophan metabolites. Estimation of their radical reactivity. Adv Exp Med Biol. 467:397-402.
39. Haldar C, Häussler D, Gupta D (1992, a). Effect of the pineal gland on circadian rhythmicity of colony forming units for granulocytes and macrophages (CFU-GM) from rat bone marrow cell cultures. J Pineal Res. 12(2):79-83.
40. Haldar C, Häussler D, Gupta D (1992, b). Response of CFU-GM (colony forming units for granulocytes and macrophages) from intact and pinealectomized rat bone marrow to murine recombinant interleukin-3 (rII-3), recombinant granulocytemacrophage colony stimulating factor (rGM-CSF) and human recombinant erythropoietin (rEPO). Prog Brain Res. 91:323-5.
41. Hardeland R (1999). Melatonin and 5-methoxytryptamine in non-metazoans. Reprod Nutr Dev. 39(3):399-408.
42. Herrera J, Nava M, Romero F, Rodríguez-Iturbe B (2001). Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis. 37(4):750-7.
43. Hirata F, Hayaishi O, Tokuyama T, Seno S (1974). In vitro and in vivo formation of two new metabolites of melatonin. J Biol Chem. 249(4):1311- 3.
44. Hörl WH (2002). Adjunctive therapy in anaemia management. Nephrol Dial Transplant. 17 Suppl 5:56-9.
45. Hu CL, Liu Z, Gao ZY et al. (2005). 2-iodomelatonin prevents apoptosis of cerebellar granule neurons via inhibition of A-type transient outward K+ currents. J Pineal Res. 38(1):53-61.
46. Huan C, Zhou M, Wu M et al. (2001). Activation of melatonin receptor increases a delayed rectifier K+ current in rat cerebellar granule cells. Brain Res. 917(2):182-90.
47. lanǎş O, Olinescu R, Bǎdescu I (1991). Melatonin involvement in oxidative processes. Endocrinologie. 29(3-4):147-53.
48. Jaworek J, Nawrot-Porabka K, Leja-Szpak A et al. (2007). Melatonin as modulator of pancreatic enzyme secretion and pancreatoprotector. J Physiol Pharmacol. 58 Suppl 6:65-80.
49. Jung FJ, Yang L, Härter L et al. (2004). Melatonin in vivo prolongs cardiac allograft survival in rats. J Pineal Res. 37(1):36-41.
50. Kang JC, Ahn M, Kim YS et al. (2001). Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J Vet Sci. 2(2):85-9.
51. Kaptanoglu E, Palaoglu S, Demirpence E et al. (2003). Different responsiveness of central nervous system tissues to oxidative conditions and to the antioxidant effects of melatonin. J Pineal Res. 34(1):32-35.
52. Kast RE, Altschuler EL (2006). Co-administration of ramelton and fluvoxamine to increase levels of interleukin-2. Med Hypotheses. 67(6):1389-90.
53. Kedziora-Kornatowska K, Szewczyk-Golec K, Czuczejko J et al. (2007). Effect of melatonin on the oxidative stress in erythrocytes of healthy young and elderly subjects. J Pineal Res. 42(2):153-8.
54. Kvetnoy IM (1999). Extrapineal melatonin: location and role within diffuse neuroendocrine system. Histochem J. 31(1):1-12.
55. Koc M, Buyukokuroglu ME, Taysi S (2002). The effect of melatonin on peripheral blood cells during total body irradiation in rats. Biol Pharm Bull. 25(5):656-7.
56. Konturek SJ, Konturek PC, Brzozowska I et al. (2007). Localization and biological activities of melatonin in intact and diseased gastrointestinal tract (GIT). J Physiol Pharmacol. 58(3):381-405.
57. Korf HW (1994). The pineal organ as a component of the biological clock. Phylogenetic and ontogenetic considerations. Ann N Y Acad Sci. 719:13-42.
58. Korkmaz A (2008). Melatonin as an adjuvant therapy in patients with rheumatoid arthritis. Br J Clin Pharmacol. 66(2):316-7.
59. Kornblihtt LI, Finocchiaro L, Molinas FC (1993). Inhibitory effect of melatonin on platelet activation induced by collagen and arachidonic acid. J Pineal Res. 14(4):184-91.
60. Labonia W, Rubio D, Arias C (2005). Melatonin corrects reticuloendothelial blockade and iron status in haemodialysed patients. Nephrology (Carlton). 10(6):583-7.
61. Labunets IF, Butenko GM, Khavinson VKh (2004). Effects of bioactive factors of the pineal gland on thymus function and cell composition of the bone marrow and spleen in mice of different age. Bull Exp Biol Med. 137(5):510-2.
62. Launay JM, Lamaître BJ, Husson HP et al. (1982). Melatonin synthesis by rabbit platelets. Life Sci. 31(14):1487-94.
63. Leach CM, Thorburn GD (1980). A comparison of the inhibitory effects of melatonin and indomethacin on platelet aggregation and thromboxane release. Prostaglandins. 20(1):51-6.
64. Leaden PJ, Catalá A (2007). Melatonin and N-acetyl serotonin inhibit selectively enzymatic and non-enzymatic lipid peroxidation of rat liver microsomes. Prostaglandins Leukot Essent Fatty Acids. 77(1):29-35.
65. Lialiaris T, Lyratzopoulos E, Papachristou F et al. (2008). Supplementation of melatonin protects human lymphocytes in vitro from the genotoxic activity of melphalan. Mutagenesis. 23(5):347-54.
66. Lissoni P, Bastone A, Sala R et al. (1987).The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels. Eur J Cancer Clin Oncol. 23(7):949-57.
67. Lissoni P, Barni S, Brivio F et al. (1995, a). A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia. Oncology. 52(5):360-2.
68. Lissoni P, Barni S, Brivio F et al. (1995, b). Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study. J Biol Regul Homeost Agents. 9(2):52-4.
69. 3: a biological phase-ll study. J Biol Regul Homeost Agents. 9(4):155-8.
70. Lissoni P, Tancini G, Barni S et al. (1996). The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia. Recenti Prog Med. 87(12):582-5.
71. Lissoni P (2007). Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent. Pathol Biol (Paris). 55(3-4): 198-200.
72. Liu F, Ng TB, Fung MC (2001 ). Pineal indoles stimulate the gene expression of immunomodulating cytokines. J Neural Transm. 108(4):397- 405.
73. Lotufo CM, Yamashita CE, Farsky SH, Markus RP (2006). Melatonin effect on endothelial cells reduces vascular permeability induced by leukotriene B4. Eur J Pharmacol. 534(1-3):258-63.
74. Lu T, Galijasevic S, Abdulhamid I, Abu-Soud HM (2008). Analysis of the mechanism by which melatonin inhibits human eosinophil peroxidase. Br J Pharmacol. 154(6):1308-17.
75. Maestroni GJ (1995). T-helper-2 lymphocytes as a peripheral target of melatonin. J Pineal Res. 18(2):84-9.
76. Maestroni GJ (1998). Is hematopoiesis under the influence of neural and neuroendocrine mechanisms? Histol Histopathol. 13(1):271-4.
77. Maestroni GJ (1999). MLT and the immune-hematopoietic system. Adv Exp Med Biol. 460:395-405.
78. Majewska M, Zajac K, Zemelka M, Szczepanik M (2007). Influence of melatonin and its precursor L-tryptophan on Th1 contact hypersensitivity. J Physiol Pharmacol. 58 Suppl 6:125-32.
79. Markus RP, Ferreira ZS, Fernandes PA, Cecon E (2007). The immune-pineal axis: a shuttle between endocrine and paracrine melatonin sources. Neuroimmunomodulation. 14(3-4):126-33.
80. Martin V, Sainz RM, Antolin I et al. (2002). Several antioxidant pathways are involved in astrocyte protection by melatonin. J Pineal Res. 33(4):204-212.
81. Mauri R, Lissoni P, Resentini M et al. (1985). Effects of melatonin on PRL secretion during different photoperiods of the day in prepubertal and pubertal healthy subjects. J Endocrinol Invest. 8(4):337-41.
82. Mayo JC, Sainz RM, Uria H et al. (1998). Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease. J Pineal Res. 24(3):179-92.
83. Mayo JC, Sainz RM, Antolin I et al. (2002). Melatonin regulation of antioxidant enzyme gene expression. Cell Mol Life Sci. 59(10):1706- 1713.
84. Melchiorri D, Ortiz GG, Reiter RJ et al. (1998). Melatonin reduces paraquat-induced genotoxicity in mice. Toxicol Lett. 95(2):103-8.
85. Mogulkoc R, Baltaci AK, Aydin L et al. (2006). Pinealectomy increases oxidant damage in kidney and testis caused by hyperthyroidism in rats. Cell Biochem Funct. 24(5):449-53.
86. Morera AL, Abreu P (2005). Existence of melatonin in human platelets. J Pineal Res. 39(4):432-3.
87. Naranjo MC, Guerrero JM, Rubio A et al. (2007). Melatonin biosynthesis in the thymus of humans and rats. 64(6):781-90.
88. Paterson PY, Hanson MA (1969). Cyclophosphamide inhibition of experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats. J Immunol. 103(6):1311-6.
89. Peña C, Rincon J, Pedreanez A et al. (2007). Chemotactic effect of melatonin on leukocytes. J Pineal Res. 43(3):263-9.
90. Persengiev SP, Kyurkchiev S (1993). Selective effect of melatonin on the proliferation of lymphoid cells. Int J Biochem. 25(3):441-4.
91. Pieri C, Marra M, Moroni F et al. (1994). Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci. 55(15):PL271- 6.
92. Poeggeler B, Reiter RJ, Tan DX et al. (1993). Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res. 14(4):151-68.
93. Pozo D, Delgado M, Fernandez-Santos JM et al. (1997). Expression of the Mel1a-melatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen. Faseb J. 11(6):466-73.
94. Raikhlin NT, Kvetnoy IM (1976). Melatonin and enterochromaffine cells. Acta Histochem.55(1):19-24.
95. Rapozzi V, Zorzet S, Comelli M (1998). Melatonin decreases bone marrow and lymphatic toxicity of adriamycin in mice bearing TLX5 lymphoma. Life Sci. 63(19):1701-13.
96. Regodón S, del Prado Míguez M, Jardín I et al. (2009). Melatonin, as an adjuvant-like agent, enhances platelet responsiveness. J Pineal Res. 46(3):275-85.
97. Reiter RJ, Tan DX, Cabrera J, D'Arpa D (1999). Melatonin and tryptophan derivatives as free radical scavengers and antioxidants. Adv Exp Med Biol. 467:379-87.
98. Reiter RJ, Acuña-Castroviejo D, Tan DX, Burkhardt S (2001, a). Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann N Y Acad Sci. 939:200-15.
99. Reiter RJ, Tan DX, Burkhardt S, Manchester LC (2001, b). Melatonin in plants. Nutr Rev. 59(9):286-90.
100. Reiter RJ, Tan DX (2003). What constitutes a physiological concentration of melatonin? J Pineal Res. 34(1):79-80.
101. Rosengarten H, Meller E, Friedhoff AJ (1972). In vitro enzymatic formation of melatonin by human erythrocytes. Res Commun Chem Pathol Pharmacol. 4(2):457-65.
102. Rossi MT, Ferrari R, Biral P, Di Bella L, Zini I (1974).Tasso leucocitario e trombopenia. Boll Soc Ital Biol Sper. Vol. L, N. 20 bis.
103. Rossi MT, Scalera G, Di Bella L (1976). Azione mielotropa della melatonina. Boll Soc Ital Biol Sper. Vol. LII, N. 18 bis.
104. Rossi MT, Di Bella L (1988). Melatonin in thrombocytogenesis.The pineal gland and cancer, edited by Gupta et al. : Brain Research Promotion. 183-94.
105. Rubio S, Estévez F, Cabrera J et al. (2007). Inhibition of proliferation and induction of apoptosis by melatonin in human myeloid HL-60 cells. J Pineal Res. 42(2):131-8.
106. Sandyk R (1990). Possible role of pineal melatonin in the mechanisms of aging. Int J Neurosci. 52(1-2):85-92.
107. Sandyk R (1993). Multiple sclerosis: the role of puberty and the pineal gland in its pathogenesis. Int J Neurosci. 68(3-4):209-25.
108. Santello FH, Frare EO, dos Santos CD et al. (2008). Suppressive action of melatonin on the TH-2 immune response in rats infected with Trypanosoma cruzi. J Pineal Res. 45(3):291-6.
109. Sarma A, Rodriguez MA, Cabanillas F et al. (2004). Recovery of natural killer cell counts after one course of CHOP chemotherapy is diminished in patients older than 60 compared to patients younger than 60.
110. Scott AE, Cosma GN, Frank AA et al. (2001) Disruption of mito chondrial respiration by melatonin in MCF-7 cells. Toxicol Appl Pharmacol. 171(3):149-56.
111. Shedpure M, Pati AK (1995). The pineal gland: structural and functional diversity. Indian J Exp Biol. 33(9):625-40.
112. Sutherland ER, Martin RJ, Ellison MC, Kraft M (2002). Immunomodulatory effects of melatonin in asthma. Am J Respir Crit Care Med. 166(8):1055- 61.
113. Szczepanik M. (2007). Melatonin and its influence on immune system. J Physiol Pharmacol. 58 Suppl 6:115-24.
114. Tan DX, Manchester LC, Reiter RJ et al. (1999). Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta. 1472(1-2):206-14.
115. Tesoriere L, D'Arpa D, Conti S et al. (1999). Melatonin protects human red blood cells from oxidative hemolysis: new insights into the radical-scavenging activity. J Pineal Res. 27(2):95-105.
116. Todisco M (2007). Melatonin makes splenectomy unnecessary in two patients with idiopathic thrombocytopenic purpura refractory to corticosteroids. J Pineal Res. 43(2):214.
117. Trubiani O, Recchioni R, Moroni F et al. (2005). Melatonin provokes cell death in human B-lymphoma cells by mitochondrial-dependent apoptotic pathway activation. J Pineal Res. 39(4):425-31.
118. Vacas Ml, Del Zar MM, Martinuzzo M, Cardinali DP (1992). Binding sites for [3H]-melatonin in human platelets. J Pineal Res. 13(2):60-5.
119. Varga Z, Panyi G, Péter M Jr et al. (2001). Multiple binding sites for melatonin on Kv1. 3. Biophys J. 80(3):1280-97.
120. Vaziri ND, Oveisi F, Reyes GA, Zhou XJ (1996). Dysregulation of melatonin metabolism in chronic renal insufficiency: role of erythropoietin deficiency anemia. Kidney Int. 50(2):653-6.
121. Vijayalaxmi, Meltz ML, Reiter RJ, Herman TS (1999). Melatonin and protection from genetic damage in blood and bone marrow: whole-body irradiation studies in mice. J Pineal Res. 27(4):221-5.
122. Viviani S, Negretti E, Orazi A et al. (1990). Preliminary studies on melatonin in the treatment of myelodysplastic syndromes following cancer chemotherapy. J Pineal Res. 8(4):347-54.
123. Wheeler AG, Dansby D, Hawkins HC et al. (2004). A toxicologic and hematologic evaluation of cyclophosphamide in experimental animals.Toxicol Appl Pharmacol. 4:324-43.
124. Yau MY, Pang CS, Kravtsov G et al. (2002). 2[125I]Iodomelatonin binding sites in guinea pig platelets. J Pineal Res. 32(2):97-105.
125. Yerer MB, Aydogan S, Yapislar H et al. (2003). Melatonin increases glutathione peroxidase activity and deformability of erythrocytes in septic rats. J Pineal Res. 35(2):138-9.
126. Yu Q, Miller SC, Osmond DG (2000). Melatonin inhibits apoptosis during early B-cell development in mouse bone marrow. J Pineal Res. 29(2):86-93.
127. Zhou MO, Jiao S, Liu Z et al. (2003). Luzindole, a melatonin receptor antagonist, inhibits the transient outward K+ current in rat cerebellar granule cells. Brain Res. 970(1-2):169-77.